Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Idara Ojofeitimi
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-8417-2568
Observed ORCID:
0000-0002-8417-2568
OpenAlex ID:
A5078924271
FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC
2021
·
Erica C. Nakajima
, Nicole Drezner
, et al.
·
Clinical Cancer Research
·
373
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
2023
·
Elizabeth S. Duke
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
106
PDF
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2022
·
Elizabeth S. Duke
, Liza Stapleford
, et al.
·
Clinical Cancer Research
·
60
PDF
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
2022
·
Elizabeth S. Duke
, Amy K. Barone
, et al.
·
Clinical Cancer Research
·
60
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer
2024
·
Michael I. Barbato
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
19
PDF
Show more works
View as search
Works count:
5
Citation count:
618
H-index:
5
I10-index:
5
Year
Topic
Type